CGT is an advanced carrier genetic test, which determines whether a couple are carriers of genetic mutations that could be transmitted to their children.
CGT uses Next-Generation Sequencing (NGS) to analyse a wide panel of disorders including as Cystic Fibrosis, Spinal Muscular Atrophy, Fragile-X Syndrome.
Uses NGS to analyse 6,600 pathogenic mutations across 547 genes linked to more than 600 genetic disorders. It is the most complete panel currently available.
Uses NGS to analyse 3,500 pathogenic mutations across 250 genes associated with the most prevalent diseases.
Recommended in cases where the person has a family history and believes they carry a mutation in a specific gene. CGT One uses NGS to sequence the entire gene or a panel of genes linked to the disease in order to locate the existing mutations.
Most carriers of genetic mutations don’t have a family history of these disorders.
Is a clinically validated genetic screening test based on Next-Generation Sequencing (NGS).
Our different CGT options, tailored to each patient’s needs, make it the most complete test available.
The development of the CGT panel and the concept of comprehensive carrier screening was published in a paper by Martin et al, 2015 (Fertil Steril. 2015 Nov; 104(5):1286-93).
An analysis of preconception carrier screening and genetic matching with donor gametes was presented in an abstract by Egea et al, 2016 (Fertil Steril. 2016 Oct; e329).
Results discussing the use of carrier screening to predict the risk of disorders in the Middle-Eastern population was published as an abstract by Martin et al, 2018 (Reproductive Biomedicine Online 2018; e10)
